Education
About Us
Working with TipRanks
Follow Us
Rapport Therapeutics, Inc. (RAPP)
NASDAQ:RAPP
RESEARCH TOOLSreports
RAPP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.43 - $29.74
Previous CloseN/A
Volume10.11K
Average Volume (3M)303.40K
Market Cap
$354.75M
Enterprise Value$429.97M
Total Cash (Recent Filing)$56.80M
Total Debt (Recent Filing)$1.48M
Price to Earnings (P/E)―
Beta2.17
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.14
Shares Outstanding36,496,437
10 Day Avg. Volume382,431
30 Day Avg. Volume303,399
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.22
Forecast
1Y Price Target
$38.50Price Target Upside296.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Rapport Therapeutics, Inc. News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsRAP-219 is advancing into and through the clinic as expected, which is encouraging for the company's progress.
Financial PositionRAPP has a cash position of $305.3M, providing financial runway for ongoing operations and trials.
Trial Design And EfficacyThe trial design for RAP-219 in focal epilepsy is considered superior by surveyed experts compared to traditional designs.
Bears Say
Management ChangesBradley Galer stepped down as Chief Medical Officer and the company is searching for his successor.
Regulatory HoldIND application for Phase IIa trial of RAP-219 in diabetic peripheral neuropathic pain placed on clinical hold by the FDA.
---
Ownership Overview
Currently, No data available
---
RAPP FAQ
What was Rapport Therapeutics, Inc.’s price range in the past 12 months?
Rapport Therapeutics, Inc. lowest stock price was $6.43 and its highest was $29.74 in the past 12 months.
What is Rapport Therapeutics, Inc.’s market cap?
Rapport Therapeutics, Inc.’s market cap is $354.75M.
When is Rapport Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Rapport Therapeutics, Inc.’s earnings last quarter?
Rapport Therapeutics, Inc. released its earnings results on Nov 07, 2024. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.564 by $0.064.
Is Rapport Therapeutics, Inc. overvalued?
According to Wall Street analysts Rapport Therapeutics, Inc.’s price is currently Undervalued.
Does Rapport Therapeutics, Inc. pay dividends?
Rapport Therapeutics, Inc. does not currently pay dividends.
What is Rapport Therapeutics, Inc.’s EPS estimate?
Rapport Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rapport Therapeutics, Inc. have?
Rapport Therapeutics, Inc. has 36,496,437 shares outstanding.
What happened to Rapport Therapeutics, Inc.’s price movement after its last earnings report?
Rapport Therapeutics, Inc. reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.564. Following the earnings report the stock price went up 8.343%.
Which hedge fund is a major shareholder of Rapport Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RAPP
---
Rapport Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.50 (296.09% Upside)
$38.50 (296.09% Upside)
Blogger Sentiment
Bullish
RAPP Sentiment 100%
Sector Average 75%
Sector Average 75%
Hedge Fund Trend
Decreased
By 441.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $162.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Company Description
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. (RAPP) is a biotechnology company focused on developing innovative therapies to treat neurological disorders. The company operates in the pharmaceutical and healthcare sectors, specializing in the discovery and development of small molecule therapeutics designed to modulate specific neurological targets. Rapport Therapeutics aims to address unmet medical needs by leveraging its proprietary platform and expertise in neuroscience to create novel solutions for patients with neurological conditions.
---
RAPP Stock 12 Month Forecast
Average Price Target
$38.50
▲(296.09% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Neurocrine
―
PTC Therapeutics
―
SAGE Therapeutics
―
Biohaven Ltd.
―
Best Analysts Covering RAPP
1 Year
1 Year Success Rate
1/4 ratings generated profit
1 Year Average Return
-37.77%
reiterated a buy rating 14 days ago
Copying Justin Walsh's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -37.77% per trade.
---